Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2020-11-24 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Reminder - Antisense Therapeutics SPP Closing Date 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement reminding shareholders about the closing date of a Share Purchase Plan (SPP). It discusses the SPP details, the use of funds raised, and contact information for inquiries. There are no financial statements, detailed financial results, or comprehensive reports included. The document is short (3160 characters) and serves as an update on a capital raising activity rather than a full report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2020-11-24 English
Antisense Therapeutics Dual lists on the FSE 2 pages 141.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Antisense Therapeutics Limited regarding the dual listing of its shares on the Frankfurt Stock Exchange. It provides details about the commencement of trading, the trading code, and strategic comments from company executives and partners. There is no financial data, report, or detailed analysis included. The document is short (under 5,000 characters) and serves as a formal announcement of a corporate event related to capital markets, specifically a listing update. This fits best under the category of Capital/Financing Update (CAP), as it relates to the company's capital market activities and share listing status.
2020-11-22 English
ANP Share Purchase Plan Booklet 18 pages 931.3KB
Capital/Financing Update Classification · 100% confidence The document is a Share Purchase Plan Booklet from Antisense Therapeutics Limited dated 18 November 2020. It details the terms and conditions of a share purchase offer to existing shareholders, including eligibility, issue price, participation rules, and timetable. The content focuses on a capital raising activity through a share purchase plan, describing how shareholders can apply for shares, the pricing, and legal disclaimers. There are no financial statements, audit information, earnings data, or management discussion of financial results. This document is clearly an update on a capital raising activity and not a full financial report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-11-18 English
Becoming a substantial holder 3 pages 143.4KB
Major Shareholding Notification Classification · 95% confidence The document text is very short (613 characters) and contains references to 'Substantial Shareholding Disclosure' and 'Substantial Shareholding DI801O8ue'. This indicates it is related to notifications about significant share ownership changes. The presence of terms like 'Substantial Shareholding' aligns with the category for notifications of changes in significant share ownership levels. There is no indication of financial statements, management discussion, or other report types. Therefore, the document is best classified as a Major Shareholding Notification (MRQ).
2020-11-17 English
Appendix 2A and Cleansing Notice 15 pages 433.0KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and references to previous announcements such as Appendix 3B. This type of document is a regulatory announcement related to capital markets activity, specifically the listing or quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or legal proceeding. The document is a formal regulatory filing to the exchange about securities quotation, which fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual filing, not just a brief announcement of a report publication. Therefore, the best classification is Capital/Financing Update (CAP).
2020-11-16 English
Notice of Annual General Meeting/Proxy Form 19 pages 478.5KB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes details about the meeting date, access instructions, business to be conducted, resolutions to be voted on, explanatory notes, proxy forms, and voting instructions. It references the Annual Financial Report for the year ended 30 June 2020 but does not contain the report itself. Instead, it is a notice to shareholders about the AGM, including agenda items such as adoption of the remuneration report, re-election of a director, ratification of share issues, and approval of a placement facility. The document is comprehensive and over 15,000 characters, consistent with a detailed AGM notice including explanatory notes and proxy forms. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. It is not the Annual Report (10-K) itself, nor a report publication announcement (RPA), as it contains substantive meeting and voting information. Therefore, the correct classification is AGM-R with high confidence.
2020-11-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.